Consegna Pharma Inc.
4551 Forbes Ave. | Suite 314 | Pittsburgh PA 15213 | +1.412.213.8788

Consegna Pharma Pipeline


Consegna Pharma Development Pipeline
INDICATION PROGRAM API DURATION MARKET IN SILICO IN VITRO IN VIVO POC cGMP MFG CLINICAL PATHWAY
Psychiatry CP901 Generic Risperdal®Consta® 14-day $1.4B ANDA
CP106 Risperidone 60-day $1.4B 505(b)(2)
CP103 Quetiapine 28-day $2.5B 505(b)(2)
CP110 PROPRIETARY 28-day 505(b)(2)
CP113 PROPRIETARY 28-day $2.4B 505(b)(2)
CP114 PROPRIETARY 28-day $1.3B 505(b)(2)
CP116 Glatiramer 14-day $1.0B 505(b)(2)
Oncology CP902 Generic Sandostatin LAR® 28-day $1.6B ANDA
CP904 Generic Lupron Depot® 28-day $1.7 ANDA
CP107 Octreotide 90-day $1.5B 505(b)(2)
Medical
Countermeasures
CP205 Butyrylcholinesterase 21-day $2.6B 505(b)(2)
CP215 Acute Radiation Syndrome 7-day $150M 505(b)(2)
Infectious
Disease
CP109 Antituberculosis Combo 60-day $600M 505(b)(2)
CP112 HIV PrEP 28-day $2.0B 505(b)(2)
Endocrinology CP903 Generic Bydureon® 7-day $600M ANDA
CP108 Exenatide 14-day $600M 505(b)(2)
Opioid Abuse CP216 Naloxone 24 hr $200M 505(b)(2)

* - In process


Products under patent are not for ultimate sale in countries where relevant patents have not expired.